Clearmind Medicine Reports Additional Positive Safety Results for CMND-100 in AUD Trial
CMND is trading near its 52-week low of $1.31 (15% above the low) on elevated volume (14× avg).
Summary
Clearmind Medicine reported additional positive safety results for its CMND-100 drug candidate in the second cohort of its Phase I/IIa clinical trial for Alcohol Use Disorder, reinforcing a favorable safety profile.
Key Events · Product Development and Regulatory · CMND
-
Additional Positive Safety Results
Clearmind Medicine announced additional topline positive safety results from the second cohort of its Phase I/IIa clinical trial for CMND-100, its proprietary non-hallucinogenic MEAI-based oral drug candidate for Alcohol Use Disorder (AUD).
-
Reinforces Favorable Profile
These new data points further strengthen the encouraging safety and tolerability profile previously established in the first cohort and initially reported for the second cohort on January 14, 2026, with no serious adverse events observed.
-
Clinical Trial Progress
The ongoing multinational, multicenter Phase I/IIa study is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD, with full treatment completion achieved for the second cohort.
Analysis · CMND · Life Sciences
Clearmind Medicine Inc. announced further positive safety results for its CMND-100 drug candidate in the ongoing Phase I/IIa clinical trial for Alcohol Use Disorder (AUD). These additional topline data from the second cohort reinforce the favorable safety and tolerability profile previously observed, with no serious adverse events reported. For a company facing significant going concern doubts, as disclosed in its recent 20-F filing, continued positive clinical progress is crucial for investor confidence and the long-term viability of its drug development programs. This strengthens the case for CMND-100 as a potential non-hallucinogenic treatment for AUD.
At the time of this filing, CMND was trading at $1.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2M. The 52-week trading range was $1.31 to $59.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.